124 research outputs found
Mediterranean Spotted Fever in Adults Aged Over 60 Years
Nowadays the distribution and course of Mediterranean spotted fever is characterized by an increasing number of severe cases and its complications worldwide. Age-dependent changes and processes of ageing influence to a different extent upon the course of the infectious diseases. The authors examined the course of the Mediterranean spotted fever in adults aged over 60 years. The study covered 90 elderly patients treated in the First Clinic of Infectious Diseases at St. Marina University Hospital of Varna during the period from 2000 till 2003. Of them, 58 were females (64,4%) and 32 males (35,6%). Their hospital stay was 8,5 0,12 days long (p<0,05) while that of 30 control persons aged between 18 and 57 years was 7 0,32 days long. Clinical patterns and biochemicalparameters were followed-up. The diagnosis was serologically confirmed in 28,8% of the patients. Some 79,2% of the elderly patients presented with accompanying diseases in contrast to 46,8% of the controls (p<0,001). Cardiovascular and cerebrovascular diseases occurred most commonly followed by chronic obstructive pulmonary disease, pneumopathies, diabetes mellitus, etc. One and the same patient often presented with several accompanying diseases. Contact with dogs was reported in 64,9% but tick biting - in 22% of the cases. The etiological treatment included tetracyclines and chlornitromycin or quinolones of third generation as an alternative. Pathogenetic and symptomatic therapy was also administered along with treatment of the accompanying diseases. The authors recommended the hospitalization of the elderly patients with Mediterranean spotted fever and the antibiotic therapy with chlornitromycin or quinolones of third generation of the severe forms. General practitioners' attention should be paid on the risk in such patients with delayed diagnosis and treatment
Implementing a Web-based Application for Analysis and Evaluation of Heart Rate Variability Using Serverless Architecture
This article is devoted to the development of a web-based application for analysis and evaluation of Heart Rate Variability (HRV) using serverless architecture. Advancements in information algorithms and computing technologies have been playing an increasingly important role in cardiology, as continuous monitoring of patientsβ health can be vital to their well-being.Β One physiological parameter that can be easily measured and that can provide indispensable insight into the state of the human body is the HRV.Β HRV analysis can assess not only the physiological state of the body but also provide the capability to monitor its dynamics and predict future diseases. As the research in the sphere of cardiology is constantly growing there is a multitude of new ways to assess the physiological state of patients and provide an early indicator to pathological conditions. Therefore, there is a need to bring these advances to a growing number of end-users (health-care professionals and patients) in the shortest possible time. To address this problem, this study proposes the development of a web-based application for analysis and evaluation of HRV by applying linear and nonlinear mathematical methods. The application is created using a serverless architectural approach, which allows for fast development time, as there is no need to manage server infrastructure, and for automatic scaling to dynamically match the number of requests. The developer can instead focus on implementing the logic for the HRV analysis algorithms and deliver new improvements at a faster rate. The proposed web application can be accessed by any device that is connected to the Internet and is optimized to handle both an intermittent and a consistent volume of requests. The algorithms implemented in the web application have been validated by examining two groups of subjects (young adults and older adults) using linear and non-linear models. The obtained results from the two groups can be compared with a set of reference values (only for the linear methods) and an assessment can be made whether each studied parameter is within the normal range or outside it (its value is too high or too low). To aid the assessment for HRV, the results obtained by the linear and nonlinear analysis are presented using a set of both graphs and tables
Relativistic Jets in the Radio Reference Frame Image Database. I. Apparent Speeds from the First 5 Years of Data
We present the results of an analysis of relativistic jet apparent speeds from VLBI images in the Radio Reference Frame Image Database (RRFID). The images are snapshot VLBI images at 8 and 2 GHz using the VLBA, plus up to 10 additional antennas that provide global VLBI coverage. We have analyzed the 8 GHz images from the first 5 years of the database (1994-1998), for all sources observed at three or more epochs during this time range. This subset comprises 966 images of 87 sources. The sources in this subset have an average of 11 epochs of observation over the years 1994-1998, with the best-observed sources having 19 epochs. About half of the sources in this RRFID kinematic survey have not been previously studied with multiepoch VLBI observations. We have measured apparent speeds for a total of 184 jet components in 77 sources, of which the best-measured 94 component speeds in 54 sources are used in the final analysis. The apparent speed distribution shows a peak at low apparent speeds (consistent with stationary components), a tail extending out to apparent speeds of about 30c, and a mean apparent speed of 3.6c. A total of 36 of the sources in this paper are also included in the 2 cm VLBA survey by Kellermann et al., with similar angular resolution, sensitivity, and time range. For those sources, we present a detailed component-by-component comparison of the apparent speeds measured by the 2 cm survey and those measured in this paper. Many of the independent apparent speed measurements agree very well, but for approximately 25% of the components we find significant differences in the apparent speeds measured by the two surveys. The leading cause of these discrepancies is differences in how the two surveys have identified jet components from epoch to epoch
PECULIARITIES OF THE EPIDEMIC PROCESS OF EPIDEMIC PAROTITIS UNDER THE CONDITIONS OF MASS IMMUNOPROPHYLAXIS
Some specific features of the mumps epidemic process under the conditions of mass immunoprevention were analyzed. Incidence rates were higher when there was a remoteness of the primary immunization by live parotitis vaccine. Certain opportunities for amending the epidemic control with this vaccine to avoid infection were emphasized
ΠΠ°ΡΠΈΠΎΠ½Π°Π»Π΅Π½ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΡ Π·Π° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ°, Π»Π΅ΡΠ΅Π½ΠΈΠ΅, ΠΏΡΠΎΡΠ»Π΅Π΄ΡΠ²Π°Π½Π΅ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° Π½Π° Ρ Π΅ΡΠ΅Π΄ΠΈΡΠ°ΡΠ½Π°ΡΠ° ΡΡΠ°Π½ΡΡΠΈΡΠ΅ΡΠΈΠ½ΠΎΠ²Π°ΡΠ° Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄ΠΎΠ·Π°
ΠΠΌΠΈΠ»ΠΎΠΈΠ΄ΠΎΠ·ΠΈΡΠ΅ ΡΠ° ΡΠΈΡΠΎΠΊ ΡΠΏΠ΅ΠΊΡΡΡ ΠΎΡ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ, Π΄ΡΠ»ΠΆΠ°ΡΠΈ ΡΠ΅ Π½Π° ΠΏΡΠΎΠΌΠ΅Π½ΠΈ Π² Π±Π΅Π»ΡΡΡΠ½Π°ΡΠ° ΡΡΡΡΠΊΡΡΡΠ°, Π² ΡΠ΅Π·ΡΠ»ΡΠ°Ρ Π½Π° ΠΊΠΎΠ΅ΡΠΎ Π½ΠΎΡΠΌΠ°Π»Π½ΠΎ ΡΠ°Π·ΡΠ²ΠΎΡΠΈΠΌ ΡΠ΅ΡΡΠ°ΠΌΠ΅ΡΠ΅Π½ Π±Π΅Π»ΡΡΠΊ ΡΠ»Π΅Π΄ Π΄Π΅ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Π½Π° ΡΠ΅ΡΠ²ΡΡΡΠΈΡΠ½Π°ΡΠ° ΡΡΡΡΠΊΡΡΡΠ° ΠΈ ΠΏΠΎΡΠ»Π΅Π΄Π²Π°Ρ ΡΠ°Π·ΠΏΠ°Π΄ Π΄ΠΎ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΈ ΠΌΠΎΠ½ΠΎΠΌΠ΅ΡΠΈ ΠΎΠ±ΡΠ°Π·ΡΠ²Π° Π½Π΅ΡΠ°Π·ΡΠ²ΠΎΡΠΈΠΌΠΈ ΠΈΠ·Π²ΡΠ½ΠΊΠ»Π΅ΡΡΡΠ½ΠΈ ΡΠΈΠ±ΡΠΈΠ»Π½ΠΈ Π΄Π΅ΠΏΠΎΠ·ΠΈΡΠΈ, ΠΊΠΎΠ΅ΡΠΎ Π²ΠΎΠ΄ΠΈ Π΄ΠΎ ΠΎΡΠ³Π°Π½Π½Π° Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ. ΠΡΠΈΡΠΊΠΈ Π²ΠΈΠ΄ΠΎΠ²Π΅ Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄ ΡΡΠ΄ΡΡΠΆΠ°Ρ Π΅Π΄ΠΈΠ½ ΠΎΡΠ½ΠΎΠ²Π΅Π½ ΡΠΈΠ±ΡΠΈΠ»Π΅Π½ ΠΏΡΠΎΡΠ΅ΠΈΠ½, ΠΊΠΎΠΉΡΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Ρ Π²ΠΈΠ΄Π° Π½Π° Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄Π°, ΠΊΠ°ΠΊΡΠΎ ΠΈ ΠΏΠΎ-ΠΌΠ°Π»ΠΊΠΈ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΈ. ΠΠ°Π΄ 20 ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ ΡΠΈΠ±ΡΠΈΠ»Π½ΠΈ ΠΏΡΠΎΡΠ΅ΠΈΠ½Π°, Π°ΡΠΎΡΠΈΠΈΡΠ°Π½ΠΈ Ρ Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄ΠΎΠ·ΠΈ ΡΠ° ΠΎΠΏΠΈΡΠ°Π½ΠΈ ΠΏΡΠΈ Ρ
ΠΎΡΠ°, Π²ΡΡΠΊΠ° ΠΎΡ ΠΊΠΎΠΈΡΠΎ ΠΈΠΌΠ° ΡΠ°Π·Π»ΠΈΡΠ½Π° ΠΊΠ»ΠΈΠ½ΠΈΡΠ½Π° ΠΊΠ°ΡΡΠΈΠ½Π°. ΠΠ΄ΠΈΠ½ ΡΠ°ΠΊΡΠ² Π±Π΅Π»ΡΡΠΊ, ΠΊΠΎΠΉΡΠΎ ΡΠΎΡΠΌΠΈΡΠ° ΡΠΎΠ²Π΅ΡΠΊΠΈ Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄Π½ΠΈ ΡΠΈΠ±ΡΠΈΠ»ΠΈ, Π΅ ΡΡΠ°Π½ΡΡΠΈΡΠ΅ΡΠΈΠ½Π° (Ando Y. ΠΈ ΡΡΡΡ. 2005). TTΠ Π΄Π΅ΠΉΡΡΠ²Π° ΠΊΠ°ΡΠΎ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ΅Π½ Π±Π΅Π»ΡΡΠΊ Π·Π° ΡΠΈΡΠΎΠΊΡΠΈΠ½ Π² ΠΏΠ»Π°Π·ΠΌΠ°. TTΠ ΡΡΡΠΎ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠΈΡΠ° ΡΠ΅ΡΠΈΠ½ΠΎΠ» (Π²ΠΈΡΠ°ΠΌΠΈΠ½ Π) ΡΡΠ΅Π· ΡΠ²ΡΡΠ·Π²Π°Π½Π΅ΡΠΎ ΠΌΡ Ρ ΡΠ΅ΡΠΈΠ½ΠΎΠ»-ΡΠ²ΡΡΠ·Π²Π°ΡΠΈΡ ΠΏΡΠΎΡΠ΅ΠΈΠ½. Π’ΠΎΠΉ ΡΠΈΡΠΊΡΠ»ΠΈΡΠ° ΠΊΠ°ΡΠΎ ΡΠ΅ΡΡΠ°ΠΌΠ΅Ρ ΠΎΡ ΡΠ΅ΡΠΈΡΠΈ ΠΈΠ΄Π΅Π½ΡΠΈΡΠ½ΠΈ ΡΡΠ±Π΅Π΄ΠΈΠ½ΠΈΡΠΈ. TTΠ ΠΌΠΎΠΆΠ΅ Π΄Π° Π±ΡΠ΄Π΅ ΠΎΡΠΊΡΠΈΡ Π² ΠΏΠ»Π°Π·ΠΌΠ°ΡΠ° ΠΈ Π»ΠΈΠΊΠ²ΠΎΡΠ°.
Π‘ΠΈΠ½ΡΠ΅Π·ΠΈΡΠ° ΡΠ΅ Π³Π»Π°Π²Π½ΠΎ Π² ΡΠ΅ΡΠ½ΠΈΡ Π΄ΡΠΎΠ± ΠΈ Ρ
ΠΎΡΠΈΠΎΠΈΠ΄Π½ΠΈΡ ΠΏΠ»Π΅ΠΊΡΡΡ Π½Π° ΠΌΠΎΠ·ΡΠΊΠ° ΠΈ Π² ΠΏΠΎ-ΠΌΠ°Π»ΠΊΠ° ΡΡΠ΅ΠΏΠ΅Π½ - Π² ΡΠ΅ΡΠΈΠ½Π°ΡΠ°. ΠΠ΅Π½ΡΡ TTΠ Π΅ Π»ΠΎΠΊΠ°Π»ΠΈΠ·ΠΈΡΠ°Π½ Π²ΡΡΡ
Ρ Π΄ΡΠ»Π³ΠΎΡΠΎ ΡΠ°ΠΌΠΎ Π½Π° Ρ
ΡΠΎΠΌΠΎΠ·ΠΎΠΌΠ° 18 ΠΈ ΡΡΠ΄ΡΡΠΆΠ° 4 Π΅ΠΊΠ·ΠΎΠ½Π° ΠΈ 3 ΠΈΠ½ΡΡΠΎΠ½Π°.
Π‘ΠΈΡΡΠ΅ΠΌΠ½ΠΈΡΠ΅ Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄ΠΎΠ·ΠΈ ΡΠ΅ ΠΎΠ·Π½Π°ΡΠ°Π²Π°Ρ Ρ Π³Π»Π°Π²Π½Π° Π±ΡΠΊΠ²Π° Π (Π·Π° Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄), ΡΠ»Π΅Π΄Π²Π°Π½Π° ΠΎΡ ΡΡΠΊΡΠ°ΡΠ΅Π½ΠΈΠ΅ΡΠΎ Π·Π° Ρ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠ°ΡΠ° ΡΡΡΠ½ΠΎΡΡ Π½Π° ΡΠΈΠ±ΡΠΈΠ»Π½ΠΈΡ ΠΏΡΠΎΡΠ΅ΠΈΠ½. Π’Π°ΠΊΠ° Π½Π°ΠΏΡΠΈΠΌΠ΅Ρ, TTΠ Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄ΠΎΠ·Π° ΡΠ΅ ΡΡΠΊΡΠ°ΡΠ°Π²Π° ATTΠ , Π° Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄ΠΎΠ·Π° ΠΏΡΠΈ ΠΎΡΠ»Π°Π³Π°Π½Π΅ Π½Π° Π»Π΅ΠΊΠΈΡΠ΅ Π²Π΅ΡΠΈΠ³ΠΈ Π½Π° ΠΈΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ΠΈΡΠ΅ β AΠ (Saraiva M. ΠΈ ΡΡΡΡ., 1984; Connors L. ΠΈ ΡΡΡΡ., 2003; Ando Y. ΠΈ ΡΡΡΡ. 2005).
ΠΠ»Π°ΡΠΈΡΠΈΡΠΈΡΠ°Π½Π΅ΡΠΎ Π½Π° ΠΎΡΠΊΡΠΈΡΠΈΡΠ΅ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈ Π²Π°ΡΠΈΠ°Π½ΡΠΈ Π΅ ΠΎΡ ΠΈΠ·ΠΊΠ»ΡΡΠΈΡΠ΅Π»Π½ΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π·Π° ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈΡΠ΅ ΡΠ΅ΡΡΠΎΠ²Π΅ ΠΈ ΡΡΡ
Π½Π°ΡΠ° ΠΈΠ½ΡΠ΅ΡΠΏΡΠ΅ΡΠ°ΡΠΈΡ. ΠΡΠ΅Π½ΠΊΠ°ΡΠ° Π½Π° ΠΏΠ°ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΡΠ° Π½Π° Π΄Π°Π΄Π΅Π½ Π³Π΅Π½Π΅ΡΠΈΡΠ΅Π½ Π²Π°ΡΠΈΠ°Π½Ρ ΡΡΡΠ±Π²Π° Π΄Π° ΡΠ΅ ΠΈΠ·Π²ΡΡΡΠ²Π° Π½Π° Π±Π°Π·Π°ΡΠ° Π½Π° Π½Π°ΡΡΠ½ΠΈ Π΄ΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΡΠ²Π° ΠΈ ΡΠΏΠΎΡΠ΅Π΄ ΡΠ½ΠΈΡΠΈΡΠΈΡΠ°Π½Π° Π½ΠΎΠΌΠ΅Π½ΠΊΠ»Π°ΡΡΡΠ° ΠΈ ΠΏΡΠ°Π²ΠΈΠ»Π°. ΠΡΠ² Π²ΡΡΠ·ΠΊΠ° Ρ ΡΠΎΠ²Π°, ΡΠΈΡΠΎΠΊΠΎ ΠΈΠ·ΠΏΠΎΠ»Π·Π²Π°Π½ΠΈΡΠ΅ Π΄ΠΎ ΠΌΠΎΠΌΠ΅Π½ΡΠ° ΡΠ΅ΡΠΌΠΈΠ½ΠΈ ΠΌΡΡΠ°ΡΠΈΡ ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΡΠΌ ΡΠ° Π·Π°ΠΌΠ΅Π½Π΅Π½ΠΈ Ρ ΠΊΠ»Π°ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ Π½Π° Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈΡΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΠΈ, ΡΠΏΠΎΡΠ΅Π΄ ΠΊΠΎΡΡΠΎ ΡΠ΅ ΠΎΠ±ΠΎΡΠΎΠ±ΡΠ²Π°Ρ 5 ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ: ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π½, Π²Π΅ΡΠΎΡΡΠ½ΠΎ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π½, Π²Π°ΡΠΈΠ°Π½Ρ Ρ Π½Π΅ΡΡΠ½ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½ΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅, Π²Π΅ΡΠΎΡΡΠ½ΠΎ Π½Π΅ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π½ ΠΈ Π½Π΅ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π½ (Richards S. ΠΈ ΡΡΡΡ., 2015; Nykamp K. Π ΡΡΡΡ., 2017)
Antiproliferative properties against human breast, cervical and ovarian cancer cell lines, and antioxidant capacity of leaf aqueous ethanolic extract from Cotinus coggygria Scop
Cotinus coggygria Scop. leaf aqueous ethanolic extract was examined for its in vitro antiproliferative and antioxidant activity. Antiproliferative effect was assessed on four human gynecological cancer cell lines: breast (MCF7, T47D), cervical (HeLa) and ovarian (A2780) and compared to the cell growth inhibitory effect on non-cancerous breast epithelial cell line MCF10A using MTT cell proliferation assay. Radical scavenging assay with DPPH was applied to evaluate antioxidant potential of the extract. The obtained results showed that the herb inhibited cell growth of all of the tested cancer cell lines and the highest was the cytostatic effect on A2780 cells with a half maximal inhibitory concentration (IC50) value of 30.8 ΞΌg/ml. For the other cell lines the IC50 values were in the range of 55-122.7 ΞΌg/ml. Additionally, the extract exerted considerably weaker reduction in cell proliferation of the non-cancerous cell line MCF10A compared to cancer cells, which indicates for antiproliferative selectivity. C. coggygria extract showed high free radical scavenging activity with an IC50 value of 11.2 ΞΌg/ml. The obtained data provide evidence for pharmacological potential of the tested extract and future more detailed studies concerning the molecular mechanisms of the anticancer effect of the herb are needed
- β¦